Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning

Journal of Toxicology - Clinical Toxicology

Volumn 37, Issue 6, 1999, Pages 731-751

  Brent, J ^a   Jaeger, A ^a   McGuigan, M ^a   Meulenbelt, J ^a   Tenenbein, M ^a   Bradberry, S ^a   Cage, S ^a   Dodd, M ^a   Harrison, W ^a   Jones, G ^a   Reeves, B ^a   Watt, B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; AMITRIPTYLINE; ASTEMIZOLE; CARBAMAZEPINE; CARBON; CHLORPROPAMIDE; DAPSONE; DEXTROPROPOXYPHENE; DIGITOXIN; DIGOXIN; DISOPYRAMIDE; DOXEPIN; IMIPRAMINE; LAXATIVE; MEPROBAMATE; METHOTREXATE; NADOLOL; NORTRIPTYLINE; PARACETAMOL; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; QUININE; SOTALOL; THEOPHYLLINE; TOBRAMYCIN; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN;

AREA UNDER THE CURVE; BEZOAR; CLINICAL TRIAL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG INDICATION; DRUG INTOXICATION; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW;

ACUTE DISEASE; ANIMALS; CARBAMAZEPINE; CATHARTICS; CHARCOAL; DAPSONE; DRUG THERAPY, COMBINATION; HUMANS; PHENOBARBITAL; POISONING; QUININE; THEOPHYLLINE;

ANIMALIA; CINCHONA PUBESCENS;

EID: 0032716099     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-100102451     Document Type: Review

References (124)

1. Chyka PA, Holley JE, Mandrell TD, Sugathan P. Correlation of drug pharmacokinetics and effectiveness of multiple-dose activated charcoal therapy. Ann Emerg Med 1995;25:356-362.
2. Arimori K, Nakano M. Accelerated clearance of intravenously administered theophylline and phenobarbital by oral doses of activated charcoal in rats. A possibility of the intestinal dialysis. J Pharmacobiodyn 1986;9:437-441.
3. Arimori K, Nakano M. The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. J Pharmacobiodyn 1987;10:157-165.
4. Johnson D, Eppler J, Giesbrecht E, et al. Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. Ann Emerg Med 1995;26:569-574.
5. Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenyl-butazone in man. Eur J Clin Pharmacol 1980;17:51-57.
6. Neuvonen PJ, Elonen E, Mattila MJ. Oral activated charcoal and dapsone elimination. Clin Pharmacol Ther 1980;27:823-827.
7. Kärkkäinen S, Neuvonen PJ. Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics. Int J Clin Pharmacol Ther 1985;23:219-225.
8. Park GD, Goldberg MJ, Spector R, et al. The effects of activated charcoal on digoxin and digitoxin clearance. Drug Intell Clin Pharm 1985;19:937-941.
9. Reissell P, Manninen V. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides. Acta Med Scand 1982;668(Suppl):88-90.
10. Lalonde RL, Deshpande R, Hamilton PP, McLean WM, Greenway DC. Acceleration of digoxin clearance by activated charcoal. Clin Pharmacol Ther 1985;37:367-371.
11. Arimori K, Kawano H, Nakano M. Gastrointestinal dialysis of disopyramide in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1989;27:280-284.
12. Du Souich P, Caillé G, Larochelle P. Enhancement of nadolol elimination by activated charcoal and antibiotics. Clin Pharmacol Ther 1983;33:585-590.
13. Berg MJ, Berlinger WG, Goldberg MJ, Spector R, Johnson GF. Acceleration of the body clearance of phenobarbital by oral activated charcoal. N Engl J Med 1982; 307:642-644.
14. Berg MJ, Rose JQ, Wurster DE, Rahman S, Fincham RW, Schottelius DD. Effect of charcoal and sorbitol-charcoal suspension on the elimination of intravenous phenobarbital. Ther Drug Monit 1987;9:41-47.
15. Frenia ML, Schauben JL, Wears RL, Karlix JL, Tucker CA, Kunisaki TA. Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. J Toxicol Clin Toxicol 1996;34:169-175.
16. Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple-dose activated charcoal. Ann Emerg Med 1987;16:1132-1135.
17. Rowden AM, Spoor JE, Bertino JS. The effect of activated charcoal on phenytoin pharmacokinetics. Ann Emerg Med 1990;19:1144-1147.
18. Laufen H, Leitold M. The effect of activated charcoal on the bioavailability of piroxicam in man. Int J Clin Pharmacol Ther 1986;24:48-52.
19. Lockey D, Bateman DN. Effect of oral activated charcoal on quinine elimination. Br J Clin Pharmacol 1989; 27:92-94.
20. Kärkkäinen S, Neuvonen PJ. Effect of oral charcoal and urine pH on sotalol pharmacokinetics. Int J Clin Pharmacol Ther 1984;22:441-446.
21. Berlinger WG, Spector R, Goldberg MJ, Johnson GF, Quee CK, Berg MJ. Enhancement of theophylline clearance by oral activated charcoal. Clin Pharmacol Ther 1983;33:351-354.
22. Ilkhanipour K, Yealy DM, Krenzelok EP. The comparative efficacy of various multiple-dose activated charcoal regimens. Am J Emerg Med 1992;10:298-300.
23. Mahutte CK, True RJ, Michiels TM, Berman JM, Light RW. Increased serum theophylline clearance with orally administered activated charcoal. Am Rev Respir Dis 1983;128:820-822.
24. Park GD, Radomski L, Goldberg MJ, Spector R, Johnson GF, Quee CK. Effects of size and frequency of oral doses of charcoal on theophylline clearance. Clin Pharmacol Ther 1983;34:663-666.
25. Park GD, Spector R, Goldberg MJ, Johnson GF, Feldman R, Quee CK. Effect of the surface area of activated charcoal on theophylline clearance. J Clin Pharmacol 1984;24:289-292.
26. Radomski L, Park GD, Goldberg MJ, Spector R, Johnson GF, Quee CK. Model for theophylline overdose treatment with oral activated charcoal. Clin Pharmacol Ther 1984;35:402-408.
27. Barone JA, Raia JJ, Huang YC. Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated toxic ingestion model. Ann Emerg Med 1988;17:34-37.
28. Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Does multiple-dose charcoal therapy enhance salicylate excretion? Arch Intern Med 1990;150:1281-1283.
29. Ho JL, Tierney MG, Dickinson GE. An evaluation of the effect of repeated doses of oral activated charcoal on salicylate elimination. J Clin Pharmacol 1989;29:366-369.
30. Mayer AL, Sitar DS, Tenebein M. Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. Arch Intern Med 1992;152: 393-396.
31. Laine K, Kivistö KT, Neuvonen PJ. The effect of activated charcoal on the absorption and elimination of astemizole. Hum Exp Toxicol 1994;13:502-505.
32. Neuvonen PJ, Kärkkäinen S. Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther 1983;33: 386-393.
33. Al-Shareef A, Buss DC, Shetty HGM, Ali N, Routledge PA. The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. Br J Clin Pharmacol 1997;43: 109-111.
34. Davis RL, Koup JR, Roon RA, Opheim KE, Smith AN. Effect of oral activated charcoal on tobramycin clearance. Antimicrob Agents Chemother 1988;32:274-275.
35. Watson WA, Jenkins TC, Velasquez N, Schentag JJ. Repeated oral doses of activated charcoal and the clearance of tobramycin, a non-absorbable drug. J Toxicol Clin Toxicol 1987;25:171-184.
36. Davis RL, Roon RA, Koup JR, Smith AL. Effect of orally administered activated charcoal on vancomycin clearance. Antimicrob Agents Chemother 1987;31:720-722.
37. Kärkkäinen S, Neuvonen PJ. Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH. Int J Clin Pharmacol Ther 1986;24:326-332.
38. Scheinin M, Virtanen R, Iisalo E. Effect of single and repeated doses of activated charcoal on the pharmacokinetics of doxepin. Int J Clin Pharmacol Ther 1985;23: 38-42.
39. Goldberg MJ, Park GD, Spector R, Fischer LJ, Feldman RD. Lack of effect of oral activated charcoal on imipramine clearance. Clin Pharmacol Ther 1985;38:350-353.
40. Crome P, Dawling S, Braithwaite RA, Masters J, Walkey R. Effect of activated charcoal on absorption of nortriptyline. Lancet 1977;2:1203-1205.
41. Boldy DAR, Heath A, Ruddock S, Vale JA, Prescott LF. Activated charcoal for carbamazepine poisoning. Lancet 1987;1:1027.
42. Montoya-Cabrera MA, Sauceda-Garcia JM, Escalante-Galindo P, Flores-Alvarez E, Ruiz-Gomez A. Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. Arch Med Res 1996;27:485-489.
43. Neuvonen PJ, Elonen E, Haapanen EJ. Acute dapsone intoxication: Clinical findings and effect of oral charcoal and haemodialysis on dapsone elimination. Acta Med Scand 1983;214:215-220.
44. Goldberg MJ, Berlinger WG. Treatment of phenobarbital overdose with activated charcoal. JAMA 1982;247: 2400-2401.
45. Pond SM, Olson KR, Osterloh JD, Tong TG. Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. JAMA 1984; 251:3104-3108.
46. Boldy DAR, Vale JA, Prescott LF. Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal. Q J Med 1986;61:997-1002.
47. Veerman M, Espejo MG, Christopher MA, Knight M. Use of activated charcoal to reduce elevated serum phenobarbital concentration in a neonate. J Toxicol Clin Toxicol 1991;29:53-58.
48. Prescott LF, Hamilton AR, Heyworth R. Treatment of quinine overdosage with repeated oral charcoal. Br J Clin Pharmacol 1989;27:95-97.
49. Amitai Y, Yeung AC, Moye J, Lovejoy FH. Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity. Ann Intern Med 1986;105:386-387.
50. Davis R, Ellsworth A, Justus RE, Bauer LA. Reversal of theophylline toxicity using oral activated charcoal. J Fam Pract 1985;20:73-74.
51. Gal P, Miller A, McCue JD. Oral activated charcoal to enhance theophylline elimination in an acute overdose. JAMA 1984;251:3130-3131.
52. Ohning BL, Reed MD, Blumer JL. Continuous nasogastric administration of activated charcoal for the treatment of theophylline intoxication. Pediatr Pharmacol 1986;5:241-245.
53. Sessler CN, Glauser FL, Cooper KR. Treatment of theophylline toxicity with oral activated charcoal. Chest 1985;87:325-329.
54. Shannon M, Amitai Y, Lovejoy FH Jr. Multiple dose activated charcoal for theophylline poisoning in young infants. Pediatrics 1987;80:368-370.
55. True RJ, Berman JM, Mahutte CK. Treatment of theophylline toxicity with oral activated charcoal. Crit Care Med 1984;12:113-114.
56. Hillman RJ, Prescott LF. Treatment of salicylate poisoning with repeated oral charcoal. Br Med J 1985;291: 1472.
57. Vale JA. Methods to increase poison elimination. In: New Clinical Applications: Nephrology. Drugs and the Kidney. Catto GRD, ed., Lancaster: Kluwer Academic Publishers 1990;65-111.
58. Boldy DAR, Smart V, Vale JA. Multiple doses of charcoal in digoxin poisoning. Lancet 1985;2:1076-1077.
59. Lake KD, Brown DC, Peterson CD. Digoxin toxicity: Enhanced systemic elimination during oral activated charcoal therapy. Pharmacotherapy 1984;4:161-163.
60. Critchley JAJH, Critchley LAH. Digoxin toxicity in chronic renal failure: Treatment by multiple dose activated charcoal intestinal dialysis. Hum Exp Toxicol 1997;16:733-735.
61. Ibanez C, Carcas AJ, Frias J, Abad F. Activated charcoal increases digoxin elimination in patients. Int J Cardiol 1995;48:27-30.
62. Pond S, Jacobs M, Marks J, Garner J, Goldschlager N, Hansen D. Treatment of digitoxin overdose with oral activated charcoal. Lancet 1981;2:1177-1178.
63. Burkhart KK, Metcalf S, Shurnas E, et al. Exchange transfusion and multidose activated charcoal following vancomycin overdose. J Toxicol Clin Toxicol 1992;30: 285-294.
64. Kucukguclu S, Tuncok Y, Ozkan H, Guven H, Uguz A, Maltepe F. Mutliple-dose activated charcoal in an accidental vancomycin overdose. J Toxicol Clin Toxicol 1996;34:83-86.
65. Hassan E. Treatment of meprobamate overdose with repeated oral doses of activated charcoal. Ann Emerg Med 1986:15:73-76.
66. Linden CH, Rumack BH. Enhanced elimination of meprobamate by multiple doses of activated charcoal. Vet Hum Toxicol 1984;26(Suppl 2):47.
67. Gadgil SD, Damle SR, Advani SH, Vaidya AB. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treat Rep 1982;66:1169-1171.
68. Griffiths ML, Kaplan H, Monteagudo FSE. Phenytoin overdose. S Afr Med J 1987;71:471.
69. Howard CE, Roberts RS, Ely DS, Moye RA. Use of multiple-dose activated charcoal in phenytoin toxicity. Ann Pharmacother 1994;28:201-203.
70. Ros SP, Black LE. Multiple-dose activated charcoal in management of phenytoin overdose. Pediatr Emerg Care 1989;5:169-170.
71. Weichbrodt GD, Elliott DP. Treatment of phenytoin toxicity with repeated doses of activated charcoal. Ann Emerg Med 1987;16:1387-1389.
72. Weidle PJ, Skiest DJ, Forrest A. Multiple-dose activated charcoal as adjunct therapy after chronic phenytoin intoxication. Clin Pharm 1991;10:711-714.
73. Swartz CM, Sherman A. The treatment of tricyclic antidepressant overdose with repeated charcoal. J Clin Psychopharmacol 1984;4:336-340.
74. Ilett KF, Hackett LP, Dusci LJ, Paterson JW. Disposition of dothiepin after overdose: Effects of repeated-dose activated charcoal. Ther Drug Monit 1991;13:485-489.
75. Farrar HC, Herold DA, Reed MD. Acute valproic acid intoxication: Enhanced drug clearance with oral-activated charcoal. Crit Care Med 1993;21:299-301.
76. Campbell JW, Chyka PA. Physicochemical characteristics of drugs and response to repeat-dose activated charcoal. Am J Emerg Med 1992;10:208-210.
77. McKinnon RS, Desmond PV, Harman PJ, et al. Studies on the mechanisms of action of activated charcoal on theophylline pharmacokinetics. J Pharm Pharmacol 1987;39:522-525.
78. Levy G. Gastrointestinal clearance of drugs with activated charcoal. New Engl J Med 1982;307:676-678.
79. Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T. Activated charcoal interrupts enteroenteric circulation of phenobarbital. J Toxicol Clin Toxicol 1994;32: 419-424.
80. Kulig KW, Bar-Or D, Rumack BH. Intravenous theophylline poisoning and multiple-dose charcoal in an animal model. Ann Emerg Med 1987;16:842-846.
81. Lim DT, Singh P, Nourtsis S, Cruz RD. Absorption inhibition and enhancement of elimination of sustained-release theophylline tablets by oral activated charcoal. Ann Emerg Med 1986;15:1303-1307.
82. Minton NA, Henry JA. Prevention of drug absorption in simulated theophylline overdose. J Toxicol Clin Toxicol 1995;33:43-49.
83. Goldberg MJ, Spector R, Park GD, Johnson GF, Roberts P. The effect of sorbitol and activated charcoal on serum theophylline concentrations after slow-release theophylline. Clin Pharmacol Ther 1987;41:108-111.
84. Hundt HKL, Aucamp AK, Müller FO. Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage. Hum Toxicol 1983;2:607-614.
85. Vree TB, Janssen TJ, Hekster YA, Termond EFS, van de Dries ACP, Wijnands WJA. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Ther Drug Monit 1986;8:297-304.
86. Wason S, Baker RC, Carolan P, Seigel R, Druckenbrod RW. Carbamazepine overdose-The effects of multiple dose activated charcoal. J Toxicol Clin Toxicol 1992; 30:39-48.
87. Vale JA, Heath A. Carbamazepine overdose. J Toxicol Clin Toxicol 1992;30:481-482.
88. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman GA, eds., New York: McGraw-Hill 1996:1721.
89. Nilsson C, Sterner G, Idvall J. Charcoal hemoperfusion for treatment of serious carbamazepine poisoning. Acta Med Scand 1984;216:137-140.
90. De Groot G, van Heijst ANP, Maes RAA. Charcoal hemoperfusion in the treatment of two cases of acute carbamazepine poisoning. J Toxicol Clin Toxicol 1984;22: 349-362.
91. Leslie PJ, Heyworth R, Prescott LF. Cardiac complications of carbamazepine intoxication: Treatment by haemoperfusion. Br Med J 1983;286:1018.
92. Lobo PI, Spyker D, Surratt P, Westervelt FB Jr. Use of hemodialysis in meprobamate overdosage. Clin Nephrol 1977;7:73-75.
93. Goldberg MJ, Berlinger WG, Park GD. Activated charcoal in phenobarbital overdose. JAMA 1985;253:1120-1121.
94. Pond SM, Osterloh JD, Olson KR, Tong TG. Activated charcoal in phenobarbital overdose. JAMA 1985;253: 1121.
95. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman GA, eds., New York: McGraw-Hill 1996:1770.
96. Jacobsen D, Wiik-Larsen E, Dahl T, Enger E, Lunde PK. Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. Eur J Clin Pharmacol 1984; 26:109-112.
97. Verpooten GA, Heyndrickx, Zachee P, De Broe ME. Comparison of hemoperfusion and hemodialysis clearances during combined and prolonged treatment of severely poisoned patients. In: Mechanisms of Toxicity and Hazard Evaluation. Holmstedt B, Lauwerys R, Mercier M, Roberfroid M, eds., Amsterdam: Elsevier/North-Holland Biomedical Press 1980:411-414.
98. Vale JA. The medical management of acute poisoning: An evaluation of charcoal haemoperfusion MD Thesis. University of London, 1980.
99. Bateman DN, Blain PG, Woodhouse KW, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: Lack of efficacy of techniques intended to enhance elimination. Q J Med 1985;54:125-131.
100. Dupuis RE, Lichtman SN, Pollack GM. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Saf 1990;5:65-71.
101. Ilkhanipour K, Yealy DM, Krenzelok EP. Activated charcoal surface area and its role in multiple-dose charcoal therapy. Am J Emerg Med 1993;11:583-585.
102. Van de Graaff WB, Leigh Thompson W, Sunshine I, Fretthold D, Leickly F, Dayton H. Adsorbent and cathartic inhibition of enterai drug absorption. J Pharmacol Exp Ther 1982;221:656-663.
103. Hunt JN, Stubbs DF. The volume and energy content of meals as determinants of gastric emptying. J Physiol 1975;245:209-225.
104. Al-Shareef AH, Buss DC, Allen EM, Routledge PA. The effects of charcoal and sorbitol (alone and in combination) on plasma theophylline concentrations after a sustained-release formulation. Hum Exp Toxicol 1990; 9:179-182.
105. AACT/EAPCCT Position Statement: Cathartics. J Toxicol Clin Toxicol 1997;35:743-752.
106. Watson WA, Cremer KF, Chapman JA. Gastrointestinal obstruction associated with multiple-dose activated charcoal. J Emerg Med 1986;4:401-407.
107. Ray MJ, Padin DR, Condie JD, Halls JM. Charcoal bezoar. Small-bowel obstruction secondary to amitriptyline overdose therapy. Dig Dis Sci 1988;33:106-107.
108. Atkinson SW, Young Y, Trotter GA. Treatment with activated charcoal complicated by gastrointestinal obstruction requiring surgery. Br Med J 1992;305:563.
109. Mizutani T, Naito H, Oohashi N. Rectal ulcer with massive haemorrhage due to activated charcoal treatment in oral organophosphate poisoning. Hum Exp Toxicol 1991;10:385-386.
110. Goulbourne KB, Cisek JE. Small-bowel obstruction secondary to activated charcoal and adhesions. Ann Emerg Med 1994;24:108-110.
111. Gomez HF, Brent JA, Munoz DC, et al. Charcoal stercolith with intestinal perforation in a patient treated for amitriptyline ingestion. J Emerg Med 1994;12:57-60.
112. Menzies DG, Busuttil A, Prescott LF. Fatal pulmonary aspiration of oral activated charcoal. Br Med J 1988; 297:459-460.
113. Pollack MM, Dunbar BS, Holbrook PR, Fields AI. Aspiration of activated charcoal and gastric contents. Ann Emerg Med 1981;10:528-529.
114. Harris CR, Filandrinos D. Accidental administration of activated charcoal into the lung: Aspiration by proxy. Ann Emerg Med 1993;22:1470-1473.
115. Givens T, Holloway M, Wason S. Pulmonary aspiration of activated charcoal after tricyclic antidepressant overdose. Vet Hum Toxicol 1990;32:375.
116. Elliott CG, Colby TV, Kelly TM, Hicks HG. Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest 1989;96:672-674.
117. Benson B, VanAntwerp M, Hergott T. A fatality resulting from multiple dose activated charcoal therapy. Vet Hum Toxicol 1989;31:335.
118. Harsch HH. Aspiration of activated charcoal. N Engl J Med 1986;314:318.
119. Rau NR, Nagaraj MV, Prakash PS, Nelli P. Fatal pulmonary aspiration of oral activated charcoal. Br Med J 1988;297:918-919.
120. Allerton JP, Strom JA. Hypernatremia due to repeated doses of charcoal-sorbitol. Am J Kidney Dis 1991;17: 581-584.
121. Farley TA. Severe hypernatremic dehydration after use of an activated charcoal-sorbitol suspension. J Pediatr 1986;109:719-722.
122. Gazda-Smith E, Synhavsky A. Hypernatremia following treatment of theophylline toxicity with activated charcoal and sorbitol. Arch Intern Med 1990;150:689-692.
123. Garrelts JC, Watson WA, Holloway KD, Sweet DE. Magnesium toxicity secondary to catharsis during management of theophylline poisoning. Am J Emerg Med 1989;7:34-37.
124. Weber CA, Santiago RM. Hypermagnesemia. A potential complication during treatment of theophylline intoxication with oral activated charcoal and magnesium-containing cathartics. Chest 1989;95:56-59.